Evidence map›Paper›PMID 33927698›Full record

ArticleFrontiers in endocrinology2021

Maternal Serum Angiopoietin-Like 3 Levels in Healthy and Mild Preeclamptic Pregnant Women.

María Fernanda Garces, Haiver Antonio Rodriguez-Navarro, Julieth Daniela Buell-Acosta, Alvaro Javier Burgos-Cardenas, Roberto Franco-Vega, Luis Miguel Maldonado-Acosta, Javier Eslava-Schmalbach, Arturo José Parada-Baños, Andres Castro-Pinzon, Elizabeth Sanchez and 7 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 3 countries.

María Fernanda GarcesDepartment of Physiology, Universidad Nacional de Colombia, Bogota, Colombia.
Haiver Antonio Rodriguez-NavarroDepartment of Physiology, Universidad Nacional de Colombia, Bogota, Colombia.
Julieth Daniela Buell-AcostaDepartment of Physiology, Universidad Nacional de Colombia, Bogota, Colombia.
Alvaro Javier Burgos-CardenasDepartment of Internal Medicine Endocrine Unit, Universidad Nacional de Colombia, Bogota, Colombia.
Roberto Franco-VegaDepartment of Internal Medicine Endocrine Unit, Universidad Nacional de Colombia, Bogota, Colombia.
Luis Miguel Maldonado-AcostaDepartment of Internal Medicine Endocrine Unit, Universidad Nacional de Colombia, Bogota, Colombia.
Javier Eslava-SchmalbachDepartment of Surgery, Universidad Nacional de Colombia, Bogota, Colombia.
Arturo José Parada-BañosDepartment of Obstetrics and Gynecology, Universidad Nacional de Colombia, Bogota, Colombia.
Andres Castro-PinzonDepartment of Internal Medicine Endocrine Unit, Universidad Nacional de Colombia, Bogota, Colombia.
Elizabeth SanchezDepartment of Physiology, Universidad Nacional de Colombia, Bogota, Colombia.
Edith Angel-MullerDepartment of Obstetrics and Gynecology, Universidad Nacional de Colombia, Bogota, Colombia.
Ezequiel LacunzaCentro de Investigaciones Inmunológicas Básicas y Aplicadas (CINIBA), Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata, Argentina.
Justo P CastañoMaimonides Institute of Biomedical Research of Cordoba, Department of Cell Biology, University of Córdoba, Córdoba, Spain.
Carlos DieguezCIBER Physiopathology of Obesity and Nutrition (CIBERobn), Instituto de Investigaciones Sanitarias (IDIS), Department of Physiology (CIMUS), Universidad de Santiago de Compostela, Santiago de Compostela, Spain.
Rubén NogueirasCIBER Physiopathology of Obesity and Nutrition (CIBERobn), Instituto de Investigaciones Sanitarias (IDIS), Department of Physiology (CIMUS), Universidad de Santiago de Compostela, Santiago de Compostela, Spain.
Ariel Ivan Ruiz-ParraDepartment of Obstetrics and Gynecology, Universidad Nacional de Colombia, Bogota, Colombia.
Jorge Eduardo CaminosDepartment of Physiology, Universidad Nacional de Colombia, Bogota, Colombia.
Universidad Nacional de Colombia · COUniversidade de Santiago de Compostela · ESUniversidad Nacional de La Plata · ARUniversity of Córdoba · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Angiopoietin-like protein 3(ANGPTL3) is an important regulator of lipoprotein metabolism in the fed state by inhibiting the enzyme lipoprotein lipase in oxidative tissues. However, the possible role of ANGPTL3 throughout gestation and its relationship with hormonal and biochemical variables are still unknown. The aim of this study was to determinate serum ANGPTL3 level in healthy non-pregnant women, during healthy and preeclamptic pregnancy and postpartum. Methods: Serum ANGPTL3 was analyzed by enzyme-linked immunosorbent assay (ELISA), in a prospective cohort of healthy pregnant women Results: Levels of ANGPTL3 were not different between the follicular and the luteal phases of the cycle in healthy non-pregnant women. There was a significant reduction in serum ANGPTL3 levels from the first to the third trimester in healthy pregnant women compared with healthy non-pregnant and postpartum women (p <0.01). ANGPTL3 levels do not differ significantly during the three trimesters of pregnancy neither in healthy women nor in preeclamptic women. The serum levels of ANGPTL3 in women who developed preeclampsia are not statistically different from those observed in healthy pregnant women in each trimester of pregnancy. A significant lineal positive correlation was observed between serum ANGPTL3 levels and triglyceride (P =0.0186, r =0.52), very low-density lipoprotein cholesterol (P =0.0224, r =0.50), and total cholesterol levels (P =0.0220, r =0.50) in healthy non-pregnant women (P 0.05). Besides, there were no significant correlations between serum ANGPTL3 and body mass index (BMI), high-density lipoprotein cholesterol, glucose, insulin, leptin, or HOMA-IR (P >0.05). Conclusions: We describe for the first time the profile of ANGPTL3 throughout pregnancy and postpartum as well as and discussed about explore their potential contribution interactions with lipoprotein metabolism throughout pregnancy and postpartum. Thus, low levels of ANGPTL3 during pregnancy might favor lipid uptake in oxidative tissues as the main maternal energy source, while may helping to preserve glucose for use by the fetus and placenta.

Indexed as

AdolescentAdultAngiopoietin-Like Protein 3BiomarkersCase-Control StudiesFemaleFollow-Up StudiesHumansPre-EclampsiaPregnancyPregnancy TrimestersPregnant PeoplePrognosisProspective StudiesYoung AdultAngiopoietin-Like Protein 3ANGPTL3 protein, humanBiomarkersANGPTLANGPTL3insulin resistancepreeclampsiapregnancy

Identifiers

PMID33927698
PMCPMC8077029
OpenAlexW3154021948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.